Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.30 | 8.60 | -0.10% |
| CAC 40 | 7,558.16 | 57.83 | -0.76% |
| DAX 40 | 23,498.33 | 143.25 | -0.61% |
| Dow JONES (US) | 42,982.43 | 106.59 | -0.25% |
| FTSE 100 | 8,718.75 | 40.24 | -0.46% |
| HKSE | 24,348.96 | 125.71 | -0.51% |
| NASDAQ | 19,973.55 | 61.02 | 0.31% |
| Nikkei 225 | 39,448.00 | 505.93 | 1.30% |
| NZX 50 Index | 12,481.88 | 20.92 | 0.17% |
| S&P 500 | 6,092.16 | 0.02 | -0.00% |
| S&P/ASX 200 | 8,549.40 | 9.80 | -0.11% |
| SSE Composite Index | 3,459.66 | 3.68 | 0.11% |